argenx SE (ARGX)
| Market Cap | 32.80B |
| Revenue (ttm) | 1.66B |
| Net Income (ttm) | -204.35M |
| Shares Out | 59.80M |
| EPS (ttm) | -3.47 |
| PE Ratio | n/a |
| Forward PE | 174.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,094 |
| Open | 544.18 |
| Previous Close | 547.28 |
| Day's Range | 540.95 - 551.21 |
| 52-Week Range | 327.73 - 554.74 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 544.06 (-1.08%) |
| Earnings Date | Oct 29, 2024 |
About ARGX
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ... [Read more]
Financial Performance
In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $544.06, which is a decrease of -1.08% from the latest price.
News
argenx: Myositis Data Could Add Billions In Value
argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease a...
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk o...
argenx to Present at Upcoming Investor Conferences
August 28, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Biotech stocks: Which drugmakers are worth a buy?
While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation...
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART ® Hytrulo following June 21 st FDA approval On track to begin four additional registrational studies ac...
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann...
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADA...
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMP...
Argenx: Strong Setup For Outperformance In 2025
Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S....
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024
R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
argenx SE (ARGX) Q1 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications and Investor Relations Ti...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second ...
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas...
argenx: Innovation Over Losses In Autoimmune Arena
argenx stock has decreased by 22% since the last evaluation, reflecting operational challenges and market conditions. The company is facing competition in the clinic, particularly from Immunovant's IM...
argenx to Present at BofA Securities 2024 Health Care Conference
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amster...
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term...